NasdaqGM:PRCTMedical Equipment
PROCEPT BioRobotics (PRCT) Is Up 5.7% After New WATER IV Trials Expand Aquablation Testing Scope
In May 2026, PROCEPT BioRobotics reported two milestones in its WATER IV prostate cancer program: full enrollment of the 280‑patient randomized trial comparing Aquablation therapy with radical prostatectomy, and FDA IDE approval for a second global randomized study comparing Aquablation with active surveillance.
By positioning Aquablation against both the surgical standard of care and active surveillance, PROCEPT is testing whether its robotic waterjet approach can expand treatment options...